CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

QuadraMune(TM)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2739 anti-SARS-CoV-2 convalescent plasma Wiki 0.50

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Phase II Study of QuadraMune(TM) for Prevention of COVID-19 in High Risk Populations

QuadraMune(TM) is a nutritional supplement which has previously been demonstrated to possess antiinflammatory and immune modulatory activity based on in vitro and pilot in vivo studies. The current clinical trial aims to assess in a 500 volunteer trial the efficacy of QuadraMune(TM) in reducing infection in individuals at high risk of COVID-19.

NCT04421391 Covid19 Coronavirus SARS-CoV 2 Dietary Supplement: QuadraMune(TM)
MeSH:Coronavirus Infections

Primary Outcomes

Description: Prevention of COVID-19 symptoms as recorded in a daily diary

Measure: Prevention of COVID-19

Time: 12 Weeks

Secondary Outcomes

Description: Assessment of adverse events and serious adverse events will be performed.

Measure: Safety as determined by presence or absence of Adverse Events and Serious Adverse Events

Time: 12 Weeks

No related HPO nodes (Using clinical trials)